's () Stephen O'Hara looks back on 2018 following the release of their full year results
Among some of the highlights in the period was a five-year deal with Akums Drugs and Pharmaceuticals to exclusively manufacture and supply supplements and drug products containing OptiBiotix’s LPLDL bacteria strain in India.
It also has an exclusive agreement with a US company for the LPLDL that carries six-figure milestone payments.
O'Hara says the raft of agreements signed are now starting to convert to revenues because of the lag period between signing and the start of cash coming in.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of OptiBiotix Health PLC named herein, including the promotion by the Company of OptiBiotix Health PLC in any Content on the Site, the Company...
FOR OUR FULL DISCLAIMER CLICK HERE